Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

In this study, we enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used mTOR-rapamycin interaction as an exemplary case.

Abstract

Drug Affinity Responsive Target Stability (DARTS) is a robust method for detection of novel small molecule protein targets. It can be used to verify known small molecule-protein interactions and to find potential protein targets for natural products. Compared with other methods, DARTS uses native, unmodified, small molecules and is simple and easy to operate. In this study, we further enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The protein-ligand interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used the mTOR-rapamycin interaction as an exemplary case for establishment of our protocol. From the proteolytic curve we saw that the proteolysis of mTOR by pronase was inhibited by the presence of rapamycin. The dose-dependency curve allowed us to estimate the binding affinity of rapamycin and mTOR. This method is likely to be a powerful and simple method for accurately identifying novel target proteins and for the optimization of drug target engagement.

Introduction

Identifying small molecule target proteins is essential to the mechanistic understanding and development of potential therapeutic drugs1,2,3. Affinity chromatography, as a classical method for identifying the target proteins of small molecules, has yielded good results4,5. However, this method has limitations, in that chemical modification of small molecules often results in reduced or altered binding specificity or affinity. To overcome these limitations, several new strategies have recently been developed and applied to identify the small molecule targets without chemical modification of the small molecules. These direct methods for target identification of label-free small molecules include drug affinity responsive target stability (DARTS)6, stability of proteins from rates of oxidation (SPROX)7, cellular thermal shift assay (CETSA)8,9, and thermal proteome profiling (TPP)10. These methods are highly advantageous because they use natural, unmodified small molecules and rely only on direct binding interactions to find target proteins11.

Among these new methods, DARTS is a comparatively simple methodology that can easily be adopted by most labs12,13. DARTS depends on the concept that ligand-bound proteins demonstrate modified susceptibility to enzymatic degradation relative to unbound proteins. The new target protein can be detected by examination of the altered band in SDS-PAGE gel through liquid chromatography-mass spectrometry (LC-MS/MS). This approach has been successfully implemented for identification of previously unknown targets of natural products and drugs14,15,16,17,18,19. It is also powerful as a means to screen or validate binding of compounds to a specific protein20,21. In this study, we present an improvement to the experiment by monitoring the changes in protein stability with small molecules and identifying protein-ligand binding affinities. We use mTOR- rapamycin interaction as an example to demonstrate our approach.

Protocol

1. Collect and lyse cells

  1. Grow 293T cells using Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum, 2 mM glutamine and 1% antibiotics. Incubate cultures at 37 °C under 5% CO2.
    NOTE: The growth state of the cells may affect the stability of subsequent experiments.
  2. Expand cells in culture until reaching 80‒90% confluence.
  3. Mix 345 μL of cell lysis reagent (see the Table of Materials) with 25 μL of 20x protease inhibitor cocktail, 25 μL of 1 M sodium fluoride, 50 μL of 100 mM β-glycerophosphate, 50 μL of 50 mM sodium pyrophosphate, and 5 μL of 200 mM sodium orthovanadate. Keep the lysis buffer chilled on ice.
    NOTE: Other lysis buffers with various detergents (e.g., Triton X-100 or NP-40) can be used with DARTS as long as they are non-denaturing. Membrane proteins or nuclear proteins can be extracted by adding 0.4% Triton X-100 or 0.4% NP-40 to the cell lysate.
  4. Wash the cells twice with cold phosphate-buffered saline (PBS).
  5. Use a cell scraper to collect the cells in an appropriate amount of cell lysis buffer and transfer the lysing cells into a 1.5 mL tube.
    NOTE: The number of cells needed for each DARTS experiment will vary based on how much protein can be extracted from various cell lines. In general, the protein concentration of the lysate used is between 4‒6 μg/μL. One 10 cm plate of 293T cells at 85‒90% confluency, lysed with 300 μL of lysis buffer typically results in a lysate with a protein concentration of ~5 μg/μL.
  6. Mix the lysis buffer/lysing cells well and incubate the tube on ice for 10 min.
  7. Centrifuge the tube at 18,000 × g for 10 min at 4 °C.
  8. Transfer the supernatant into a new 1.5 mL tube and keep chilled on ice.
  9. Perform a BCA assay to approximate the protein concentration of lysates.

2. Incubate protein lysates with the small molecule

  1. Split 99 μL of the lysates into two 1.5 mL tubes.
  2. Make a starting stock concentration of 10 mM small molecule. When performing DARTS, one may begin with a higher concentration of the small molecule (5‒10x the EC50 value) to ensure optimal binding.
    1. Add either 1 μL of solvent that the small molecule is soluble in or 1 µL of small molecule stock solutions to each aliquot of lysate. Incubate cell lysate with the solutions for 30‒60 min at room temperature with shaking.
  3. On ice, establish serial dilutions (1:200, 1:400, 1:800 and 1:1600) of freshly thawed pronase solution in 1x TNC (For 1 mL of 10x TNC buffer, mix 300 μL of ultrapure water with 100 μL of 5 M sodium chloride, 100 μL of 1 M calcium chloride, and 500 μL of 1 M Tris-HCl, pH 8.0).
  4. Examine a wide-breadth of pronase:protein ratios (e.g., spanning from 1:100 to 1:2000) to guarantee observability of the step-wise effect of pronase on target(s).
    NOTE: To calculate pronase concentrations (example): 5 μg/μL protein concentration x 20 μL sample = 100 μg protein. For a pronase:protein ratio of 1:100 we need 0.5 μg/μL (100 μg ÷ 100 ÷ 2 μL) pronase solution. This experiment may have to be repeated several times to obtain a suitable range of pronase:protein ratios.

3. Perform proteolysis

NOTE: For proteolysis, steps are carried out at room temperature unless otherwise noted

  1. Following incubation with the small molecule, divide each aliquot into 20 μL samples.
  2. Add 2 μL of the range of pronase solutions in each sample at specific intervals (every 30 s). Use an equal volume of 1x TNC buffer to establish an undigested control sample.
  3. After 5‒20 min, halt digestion via addition of 2 μL of cold 20x protease inhibitor cocktail every 30 s. Mix well and incubate on ice for 10 min.
  4. Dilute samples with the appropriate volume of 5x SDS-PAGE loading buffer and boil at 95 °C for 5 min.
  5. Carry out the next portion of the experiment or store the protein sample at −80 °C.

4. Quantification and analysis

  1. After DARTS, perform Coomassie blue staining according to the previously published protocol22.
  2. The stained protein bands should be very clear after destaining. Pour off the used destain solution and add fresh 1% acetic acid solution to cover the gel. Put the gel under the light to observe the bands with significant differences between groups with (sample group) or without (control group) the small molecule.
  3. Cut the two corresponding bands from the gel with a sterile instrument and perform LC-MS/MS immediately.
    NOTE: LC-MS/MS needs to be done as soon as possible because the proteins in the gel will degrade continuously.
  4. Digest the bands, extract peptides and perform LC-MS/MS analysis23.
    1. To analyze LC-MS/MS data, first identify all the proteins in the individual band. Second, use peptide spectrum match (PSM) to represent the abundance of each protein.
      NOTE: PSM provides the total number of identified peptide sequences for the protein, including those redundantly identified. In general, how often a peptide is identified/sequenced can be used as a rough estimate of how abundant the protein is in the sample. Proteins enriched in the sample group over the control group are proteins of interest.
  5. Procure the primary antibodies of the selected proteins. Perform western blot to verify that the small molecule can bind directly to the potential target proteins24.
    1. Load equal amounts of protein into the wells of an 8% SDS-PAGE gel, along with an appropriate molecular weight marker. Run the gel for 30 min at 80 V, then adjust the voltage to 120 V and continue running for 1‒2 h.
  6. Quantify the different target protein bands using image processing and analysis software (see the Table of Materials).
  7. Analyze the data and draw the curves.
    1. Determination of the proteolytic curve for a target protein
      1. The pronase:protein ratio is varied when performing proteolysis. Normalize data from image analysis by attributing the band intensity values corresponding to the undigested bands to 100%.
      2. Use nonlinear regression analysis of the statistical analysis and drawing software to plot a curve of normalized data for relative band intensity and pronase:protein ratios.
      3. First, open the software, select the type of table and graph as XY and allow for 3 replicate values in side-by-side subcolumns. Then enter the corresponding data in the space below x and y. Under x, input the numbers 0, 1, 2, 3, 4, 5 (as place holders corresponding pronase:protein ratios).
      4. In the y column, enter the normalized data for relative band intensities. Perform “Nonlinear regression” and implement a “Dose-response-Stimulation” using the “Log (agonist) versus response—Variable slope (four parameters)” equation.
      5. Convert the annotations of the X-axis in the curve to the corresponding pronase:protein ratios.
    2. Determination of the dose-dependence curve for a target protein
      NOTE: For dose-dependence analysis, the molarity of the small molecule is differed across samples. The stable pronase:protein ratio should be informed by analysis of proteolysis data. The pronase:protein ratio that showed maximal difference in target protein intensity during the proteolytic curve should be used for the dose-dependence experiment.
      1. Quantify the different target protein bands using an image analysis software. As in generation of the dose-dependence curve, normalize data from image analysis by attributing the band intensity values corresponding to the least digested band to 100%.
      2. Apply the nonlinear regression analysis within the statistical analysis and drawing software to the normalized data. First, open the software, select the type of table and graph as XY, and enter 3 replicate values in side-by-side subcolumns.
      3. Then, enter the corresponding data in the space below x and y. For the ‘x’ variable, input different concentrations of the small molecule; ‘y’ includes the corresponding normalized data for relative band intensity.
      4. Transform x values using X = Log(X). Finally, employ nonlinear regression, and implement a dose-response stimulation using the “Log (agonist) versus response—Variable slope (four parameters)” equation.

Results

The flow chart of the experiment is outlined in Figure 1. The result of Coomassie blue staining is shown in Figure 2. Incubation with the small molecule confers protection against proteolysis. Three bands that appear to be protected by incubation with rapamycin over vehicle control are found. The expected results from proteolytic curve experiment are shown in Figure 3. As a proof-of-principle, we examined the well-studied protein mT...

Discussion

DARTS allows for identification of small molecule targets by exploiting the protective effect of protein binding against degradation. DARTS does not require any chemical modification or immobilization of the small molecule26. This allows small molecules to be used to determine their direct binding protein targets. Standard assessment criteria for the classical DARTS method include gel staining, mass spectrometry and western blotting12,13. ...

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported partly by NIH research grants R01NS103931, R01AR062207, R01AR061484, and a DOD research grant W81XWH-16-1-0482.

Materials

NameCompanyCatalog NumberComments
100X Protease inhibitor cocktailSigma-AldrichP8340Dilute to 20X with ultrapure water
293T cell lineATCCCRL-3216DMEM medium with 10% FBS
Acetic acidSigma-AldrichA6283
BCA Protein Assay KitThermo Fisher23225
Calcium chlorideSigma-AldrichC1016
Cell scraperThermo Fisher179693
Coomassie Brilliant Blue R-250 Staining SolutionBio-Rad1610436
Dimethyl sulfoxide(DMSO)Sigma-AldrichD2650
GraphPad PrismGraphPad SoftwareVersion 6.0statistical analysis and drawing software
Hydrochloric acidSigma-AldrichH1758
ImageJNational Institutes of HealthVersion 1.52image processing and analysis software
M-PER Cell Lysis ReagentThermo Fisher78501
Phosphate-buffered saline (PBS)CorningR21-040-CV
PronaseRochePRON-RO10 mg/ml
Sodium chlorideSigma-AldrichS7653
Sodium fluorideSigma-AldrichS7920
Sodium orthovanadateSigma-Aldrich450243
Sodium pyrophosphateSigma-Aldrich221368
Trizma baseSigma-AldrichT1503adjust to pH 8.0
β-glycerophosphateSigma-AldrichG9422

References

  1. Rask-Andersen, M., Masuram, S., Schioth, H. B. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annual Review of Pharmacology and Toxicology. 54, 9-26 (2014).
  2. O'Connor, C. J., Laraia, L., Spring, D. R. Chemical genetics. Chemical Society Reviews. 40 (8), 4332-4345 (2011).
  3. McFedries, A., Schwaid, A., Saghatelian, A. Methods for the elucidation of protein-small molecule interactions. Chemistry & Biology. 20 (5), 667-673 (2013).
  4. Sato, S., Murata, A., Shirakawa, T., Uesugi, M. Biochemical target isolation for novices: affinity-based strategies. Chemistry & Biology. 17 (6), 616-623 (2010).
  5. Sleno, L., Emili, A. Proteomic methods for drug target discovery. Current Opinion in Chemical Biology. 12 (1), 46-54 (2008).
  6. Lomenick, B., et al. Target identification using drug affinity responsive target stability (DARTS). Proceedings of the National Academy of Sciences of the United States of America. 106 (51), 21984-21989 (2009).
  7. Strickland, E. C., et al. Thermodynamic analysis of protein-ligand binding interactions in complex biological mixtures using the stability of proteins from rates of oxidation. Nature Protocols. 8 (1), 148-161 (2013).
  8. Jafari, R., et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nature Protocols. 9 (9), 2100-2122 (2014).
  9. Martinez Molina, D., et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 341 (6141), 84-87 (2013).
  10. Savitski, M. M., et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 346 (6205), 1255784 (2014).
  11. Chang, J., Kim, Y., Kwon, H. J. Advances in identification and validation of protein targets of natural products without chemical modification. Natural Product Reports. 33 (5), 719-730 (2016).
  12. Pai, M. Y., et al. Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods in Molecular Biology. 1263, 287-298 (2015).
  13. Lomenick, B., Jung, G., Wohlschlegel, J. A., Huang, J. Target identification using drug affinity responsive target stability (DARTS). Current Protocols in Chemical Biology. 3 (4), 163-180 (2011).
  14. Xu, L., et al. Precision therapeutic targeting of human cancer cell motility. Nature Communications. 9 (1), 2454 (2018).
  15. Lim, H., et al. A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nature Communications. 9 (1), 1438 (2018).
  16. Schulte, M. L., et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nature Medicine. 24 (2), 194-202 (2018).
  17. Skrott, Z., et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 552 (7684), 194-199 (2017).
  18. Zhang, C., et al. Endosidin2 targets conserved exocyst complex subunit EXO70 to inhibit exocytosis. Proceedings of the National Academy of Sciences of the United States of America. 113 (1), 41-50 (2016).
  19. Chin, R. M., et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 510 (7505), 397-401 (2014).
  20. Robinson, T. J., et al. High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle. 12 (18), 3013-3024 (2013).
  21. Aghajan, M., et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nature Biotechnology. 28 (7), 738-742 (2010).
  22. Brunelle, J. L., Green, R. Coomassie blue staining. Methods in Enzymology. 541, 161-167 (2014).
  23. Domon, B., Aebersold, R. Mass spectrometry and protein analysis. Science. 312 (5771), 212-217 (2006).
  24. Hnasko, T. S., Hnasko, R. M. The Western Blot. Methods in Molecular Biology. 1318, 87-96 (2015).
  25. Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L., Clardy, J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. Journal of Molecular Biology. 229 (1), 105-124 (1993).
  26. Lomenick, B., Olsen, R. W., Huang, J. Identification of direct protein targets of small molecules. ACS Chemical Biology. 6 (1), 34-46 (2011).
  27. Park, Y. D., et al. Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening. MBio. 7 (4), (2016).
  28. Qu, Y., et al. Small molecule promotes beta-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. 14 (1), 94-101 (2018).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

DARTS AssayDrug Affinity Responsive Target StabilityRapamycinMTOR InteractionProtein ligand Interactions293T CellsCell Lysis BufferBCA AssayProtease InhibitorSDS PAGESmall molecule InteractionsProtein StabilityExperimental Protocol

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved